



Matrix Corporate Capital LLP
One Vine Street London W1J 0AH
t +44 (0) 20 3206 7000 f +44 (0) 20 3206 7015
corporatecapital@matrixgroup.co.uk
www.matrixgroup.co.uk

For immediate release: 26 November 2009

Matrix announces FUSCIA, a new flexible funding structure for growth companies: signs first agreement with ReNeuron.

Matrix Corporate Capital LLP ("MCC") today announces that it has entered into a "Flexible Use, Small Capital Increase Agreement" (or "FUSCIA") with ReNeuron Group PLC ("ReNeuron" or the "Company").

Under the terms of the agreement, which is intended to provide ReNeuron with working capital support as it progresses its lead stem cell products through the clinic, the Company will be able to place up to £5,000,000 of equity capital with MCC, as principal, over a two year period. MCC will then use its contacts, relationships and trading expertise to place this stock into the Market.

Malcolm Le May, Chief Executive Officer of MCC, commented:

"Having already assisted ReNeuron with its £3m capital raising earlier this year, we were appointed as broker in September. We are delighted that we can now extend our relationship to provide ReNeuron with the financial support that it needs as it embarks on the groundbreaking development of its lead compound ReN001 in stroke."

"The past few years have been especially difficult for a number of growth sectors, and none more so than healthcare. We are pleased to be at the forefront of innovation in finding new ways of funding these companies, at a time when capital markets have yet to warm to riskier assets. MCC believes FUSCIA instruments are an attractive option for companies to benefit from flexible supplementary investment, for working capital purposes, at an attractive cost of capital."

ENDS

Notes for Editors

About FUSCIA

FUSCIA is a differentiated equity drawdown product which combines significant flexibility with the ability to scale funding, seamlessly and efficiently, as opportunities arise. MCC has also sought to address the issues which have previously limited the use of such products and to provide a structure which meets the specific needs of companies across a breadth of corporate profiles.

Advantages:

1. Issues new equity efficiently into the Market
2. Neither retail nor institutional investors are excluded
3. Facility is scalable with volume traded in the Market, both retrospectively and prospectively.
4. Exercisable at discretion of the company
5. Lower cost of capital: reduces discount paid on placement.
6. Reduced management time spent on fundraising
7. No short selling of the stock during pricing

Appropriate for:

1. Liquid stocks



Matrix Corporate Capital LLP
One Vine Street London W1J 0AH
t +44 (0) 20 3206 7000 f +44 (0) 20 3206 7015
corporatecapital@matrixgroup.co.uk
www.matrixgroup.co.uk

2. Companies requiring small amounts of additional working capital
3. Companies requiring £2-10 million over a 2-3 year period

ENDS

For further information please contact:

Natasha Newman

Matrix Group +44 (0) 20 3206 7130

Malcolm Le May

Steve Cox

Stephen Waterman

Matrix Corporate Capital LLP +44 20 3206 7000